FBRX — Forte Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $45.82m
- -$12.54m
Annual cashflow statement for Forte Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -46.5 | -21.7 | -13.9 | -31.5 | -35.5 |
| Depreciation | |||||
| Non-Cash Items | 31.8 | 4.28 | 4.01 | 3.15 | 2.94 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.83 | 0.72 | 1.68 | -0.392 | 1.76 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -18.4 | -16.7 | -8.19 | -28.7 | -30.7 |
| Capital Expenditures | — | — | — | -0.088 | -0.037 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.58 | 0 | — | 0.135 | -36 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 3.58 | 0 | — | 0.047 | -36 |
| Financing Cash Flow Items | -0.289 | -0.106 | 0 | -0.06 | -1.16 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 66.7 | -0.044 | 7.24 | 24.7 | 51.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 51.8 | -16.7 | -0.944 | -3.98 | -14.9 |